Mechanisms of Cognitive Control Impairment in ME/CFS and PASC-ME/CFS
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R01NS133905-01
Grant search
Key facts
Disease
COVID-19Start & end year
2023.02028.0Known Financial Commitments (USD)
$490,883Funder
National Institutes of Health (NIH)Principal Investigator
ASSISTANT PROFESSOR H EryilmazResearch Location
United States of AmericaLead Research Institution
MASSACHUSETTS GENERAL HOSPITALResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
ABSTRACT Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a symptom-based diagnosis characterized by severe debilitating fatigue, cognitive dysfunction, and widespread pain. Most cases of ME/CFS begin with a viral infection or involve multiple exposures to pathogens over time. Soon after the onset of the COVID-19 pandemic, a significant portion of patients infected with SARS-CoV-2 developed chronic symptoms that overlap greatly with those of ME/CFS. Among the post-acute sequelae of COVID-19 (PASC), "brain fog" symptoms have been widely reported including in patients with mild initiating infection. Many PASC patients meet the diagnostic criteria for ME/CFS after 6 months of ongoing symptoms (referred to herein as PASC- ME/CFS). Given the growing number of SARS-CoV-2 infections, the disease burden on individuals with ME/CFS and PASC-ME/CFS, and the challenges associated with these conditions such as rehabilitation and workforce disruptions, elucidating the mechanisms of cognitive deficits in ME/CFS and PASC-ME/CFS is of clear